Luaran Kanker Ovarium Berdasarkan Modifikasi Glasgow Prognostik Skor
DAFTAR PUSTAKA
1. Schorge JO et al, Epithelial ovarian cancer in Williams Gynecology, 1st ed.
New York, Mc Graw Hill, 2008,p 716-20
2. Nodin B. Immunohistochemical And Molecular Studies On Ovarian Cancer
Progression And Prognosis. Doctoral Dissertation. Denmark : Lund University,
Clinical Sciences; 2013. Report No.: Isbn 978-91-87449-49-9/ Issn 16528220.
3. Suhonen K. Prognostic Role of Cell Adhesion Factors and Angiogenesis in
Epithelial Ovarian Cancer. Doctoral Dissertation. Kuopio: University of Kuopio.
Clinical Medicine 2007. Report No: ISBN 978-951-27-0752-2/ ISSN 12350303
4. Aziz MF, Andrijono, Saifuddinn AB. Buku acuan Nasional Onkologi
Ginekologi. Yayasan Bina Pustaka Sarwono Prawirohardjo. Departemen
Ginekologi dan ginekologi fakultas kedokteran Indonesia. Edisi pertama.
2006; 469 – 527
5. Bugada D, Allegri M, Lavand‟home P, De Kock M, Fanelli G, Review article:
inflammation-based scores: a new method for patient targeted strategies and
improved perioperative out come in cancer patients, Hindawi publishing
corporation. Biomed research international, vol 2014, article ID 142425
6. C. A.Dinarello, “Theparadox of pro-inflammatory cytokines in cancer,” Cancer
and Metastasis Reviews, vol. 25, no. 3, pp. 307–313, 2006.
7. Sharma R, Hook J, Kumar M, Gabra H, Evaluation of an inflammation-based
prognostic score in patients with advanced ovarian cancer, european journal
of cancer 4 4 ( 2 0 0 8 ) 2 5 1 –2 5 6
8. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of
cancer cachexia. Curr Opin Clin Nutr Metab Care 2003;6:401–6.
9. Lee.S, Choe J, Kim H, Sung J, high sensitivity c-reactive protein and cancer, J
epidemiol 2011, 21(3), 161-168
10. S. Lee, S. Y. Oh, S. H. Kim et al., “Prognostic significance of neutrophil
lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer
patients treated with FOLFOX chemotherapy,” BMC Cancer, vol. 13, article
350, 2013.
11. H.-Y. Hung, J.-S. Chen, C. Y. Yeh et al., “Effect of preoperative neutrophillymphocyte ratio on the surgical outcomes of stage II colon cancer patients
who do not receive adjuvant chemotherapy,” International Journal of
Colorectal Disease, vol. 26, no. 8, pp. 1059–1065, 2011.
12. Y.Kishi, S.Kopetz, Y. S. Chun,M.Palavecino, E. K. Abdalla, and J.-N. Vauthey,
“Blood neutrophil-to-lymphocyte ratio predicts survival in patients with
colorectal livermetastases treated with systemic chemotherapy,” Annals of
Surgical Oncology, vol. 16, no. 3, pp. 614–622, 2009.
13. A. M. di Giacomo, L. Calabr`o, R. Danielli et al., “Longterm survival and
immunological parameters in metastatic melanoma patients who responded to
ipilimumab 10 mg/kg within an expanded access programme,” Cancer
Immunology, Immunotherapy, vol. 62, no. 6, pp. 1021–1028, 2013.
14. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A,
and Cramer DW, Prognostic Significance and Predictors of the Neutrophil-toLymphocyte Ratio in Ovarian Cancer Gynecol Oncol. 2014 March ; 132(3):
542–550.
15. W.He, C. Yin, G.Guo et al., “Initial neutrophil lymphocyte ratio is superior to
platelet lymphocyte ratio as an adverse prognostic and predictive factor in
metastatic colorectal cancer,” Medical Oncology, vol. 30, no. 1, article 439,
2013.
16. J. F. Feng, Y. Huang, Q. Zhao, and Q. X. Chen, “Clinical significance of
preoperative neutrophil lymphocyte ratio versus platelet lymphocyte ratio in
patients with small cell carcinoma of the esophagus,” The ScientificWorld
Journal, vol. 2013,Article ID 504365, 7 pages, 2013.
17. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S,
Thavaramara T, Platelet to lymphocyte ratio as a prognostic factor for
epithelial ovarian cancer, in J Gynecol Oncol Vol. 23, No. 4:265-273
18. N. MacDonald, “Terminology in cancer cachexia: importance and status,”
Current Opinion in Clinical Nutrition andMetabolic Care, vol. 15, no. 3, pp.
220–225, 2012.
19. M. J. Proctor,D. S.Morrison,D. Talwar et al., “An inflammationbased
prognostic score (mGPS) predicts cancer survival independent of tumour site:
a Glasgow Inflammation Outcome Study,” British Journal of Cancer, vol. 104,
no. 4, pp. 726–734, 2011.
20. Berek JS. Natarajan Sathima. Ovarian and Fallopian Tube Cancer. Berek &
Novak‟s Gynecology. Lippincott William and Wilkins. 14th edition.2007; 1457
– 1503
21. Berek JS, Friedlander M, Hacker NF, Epithelial Ovarian, Fallopian Tube, and
Peritoneal Cancer, in berek and Hacker's Gynecologic Oncology, 5th Edition.
Lippincott Williams & Wilkins 2010 p.444-509
22. Tone AA, Salvador S, Finlayson SJ et al, The Role of the Fallopian Tube in
Ovarian Cancer, Clinical Advances in Hematology & Oncology Volume 10,
Issue 5 May 2012, pp 296-306
23. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma
that originates in the distal fallopian tube. J Pathol. 2007;211:26-35.
24. Jordan SJ, Green AC, Whiteman DC, et al. Serous ovarian, fallopian tube and
primary peritoneal cancers: a comparative epidemiological analysis. Int J
Cancer. 2008;122:1598-1603.
25. Macciò A and Madeddu C, Inflammation and Ovarian Cancer, Ovarian Cancer
– Basic Science Perspective. 2012 Report No: ISBN: 978-953-307-812-0
26. Wang C, Sun C, C-Reactive Protein and Malignancy: Clinico-Pathological
Association and Therapeutic Implication. Reveiw Article, Chang Gung Med J
2009;32:471-82
27. A. T. Toriola, K. Grankvist, C. B. Agborsangaya, A. Lukanova, M. Lehtinen &
H.-M. Surcel, Changes In Pre-Diagnostic Serum C-Reactive Protein
Concentrations And Ovarian Cancer Risk: A Longitudinal Study, in Annals of
Oncology 22: 1916–1921, 2011.
28. Shan W, Liu J. Inflammation; a hidden path to breaking the spell of ovarian
cancer. Cell Cycle 2009; 8(19): 3107–3111.
29. Partheen K, New Prognostic Markers In Stage III Serous Ovarian
Adenocarcinomas, in thesis, Department of Oncology Institute of Clinical
Sciences The Sahlgrenska Academy at University of Gothenburg, 2008.
30. Elshabrani S, Farid A et.al, Evaluation of C-Reactive Protein as a Probable
Factor for Cancer Diagnosis, life sience journal, 2012, 9 (4)
31. Hefler L A, Concin N et al, Serum C-Reactive Protein as Independent
Prognostic Variable in Patiens With Ovarian Cancer, Clin Cancer Res
2008;14(3)
32. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor
proliferative
activity
in
patients
with
colorectal
carcinoma.
Cancer
1999;85:2526–31.
33. Mc Keown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship
between circulating concentrations of Creactive protein, inflammatory
cytokines and cytokine receptors in patients with non-small-cell lung cancer.
Br J Cancer 2004;91:1993–5.
34. Peralta R, Rubery BA, Langenfeld SC. Hypoalbuminemia : treatment and
medication. eMedicine Critical Care.2010.1-6.
35. Gupta D, Lis CG, Pretreatment serum albumin as a predictor of cancer
survival: A systematic review of the epidemiological literature, in Gupta and
Lis Nutrition Journal 2010.
36. Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotte P,
Lerebours E, Michel P: Baseline nutritional status is predictive of response to
treatment and survival in patients treated by definitive chemoradiotherapy for
a locally advanced esophageal cancer. Am J Gastroenterol 2007, 102:25572563.
37. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K: Inflammation-based
prognostic score is a novel predictor of postoperative outcome in patients with
colorectal cancer. Ann Surg 2007, 246:1047-1051.
38. Gupta D, Lammersfeld CA, Vashi PG, Lis CG. A longitudinal analysis
investigating the impact of improvement in serum albumin scores on survival
in ovarian cancer. Clinical Ovarian cancer. 2009;2(2):106-111.
39. Donohoe CL, Ryan AM, , cancer cachexia : mechanisms and clinical
implications, review article, hindawi publishing corp. Vol 2011.
40. Lu H, Ouyang W et al. Inflammation, a key event in cancer development
,Subject Review, mol.cancer res 2006 4(6), april 2006
41. Drenberg DC. Saunders OB. Wilbanks DG et al. Urinary Angiostatin levels are
elevated in patients with Epithelial ovarian Cancer. Gynecologic Oncology.
USA. 117:2010.117-124
42. M. J. Proctor, P. G. Horgan, D. Talwar, C. D. Fletcher, D. S. Morrison, and D.
C. McMillan, “Optimization of the systemic inflammation-based Glasgow
prognostic score: a Glasgow InflammationOutcome Study,” Cancer, vol. 119,
no. 12, pp. 2325– 2332, 2013.
43. D. C. McMillan, “The systemic inflammation-based Glasgow prognostic score:
a decade of experience in patients with cancer,” Cancer Treatment Reviews,
vol. 39, no. 5, pp. 534–540,2013.
44. Suh KS, Sang WP, Angelica C1, et al.
Ovarian cancer biomarkers for
molecular biosensors and translational medicine Expert Rev. Mol. Diagn.
10(8), 1069–1083. 2010.
45. Former Anglia Cancer Network. Cancer Research UK. Http://ecric.org.uk/
46. Rauh-Hain AJ, Del Carmen MG, Recurrent Epithelial Ovarian Cancer: An
Update on Treatment. cancer network home of the journal oncology. Reveiw
article 2013. Published on Cancer Network http://www.cancer net work.com
47. FIGO 1988 VS FIGO 2013 Ovarian Cancer Staging Guide.
48. Madiyono B, Mz Sm, Sastoasmoro S, Budiman I, Purwanto S H. Perkiraan
Besar Sampel. Dalam Sastroasmoro S, Ismael S. Dasar Dasar Metodologi
Penelitian Klinis. Jakarta: Sagung Seto; 2010. p. 323.
49. Hs-CRP Kit, Pramita Laboratorium Leaflet. 2012
50. Pemeriksaan CRP, Prosedur Tetap Pelayanan Laboratorium, RSUP H.Adam
Malik, Medan, Juli 2012
51. Bmi asia WHO expert consultation in Appropriate body-mass index for Asian
populations and its implications for policy and intervention Strategies. Public
Health. The Lancet • Vol 363 • January 10, 2004
1. Schorge JO et al, Epithelial ovarian cancer in Williams Gynecology, 1st ed.
New York, Mc Graw Hill, 2008,p 716-20
2. Nodin B. Immunohistochemical And Molecular Studies On Ovarian Cancer
Progression And Prognosis. Doctoral Dissertation. Denmark : Lund University,
Clinical Sciences; 2013. Report No.: Isbn 978-91-87449-49-9/ Issn 16528220.
3. Suhonen K. Prognostic Role of Cell Adhesion Factors and Angiogenesis in
Epithelial Ovarian Cancer. Doctoral Dissertation. Kuopio: University of Kuopio.
Clinical Medicine 2007. Report No: ISBN 978-951-27-0752-2/ ISSN 12350303
4. Aziz MF, Andrijono, Saifuddinn AB. Buku acuan Nasional Onkologi
Ginekologi. Yayasan Bina Pustaka Sarwono Prawirohardjo. Departemen
Ginekologi dan ginekologi fakultas kedokteran Indonesia. Edisi pertama.
2006; 469 – 527
5. Bugada D, Allegri M, Lavand‟home P, De Kock M, Fanelli G, Review article:
inflammation-based scores: a new method for patient targeted strategies and
improved perioperative out come in cancer patients, Hindawi publishing
corporation. Biomed research international, vol 2014, article ID 142425
6. C. A.Dinarello, “Theparadox of pro-inflammatory cytokines in cancer,” Cancer
and Metastasis Reviews, vol. 25, no. 3, pp. 307–313, 2006.
7. Sharma R, Hook J, Kumar M, Gabra H, Evaluation of an inflammation-based
prognostic score in patients with advanced ovarian cancer, european journal
of cancer 4 4 ( 2 0 0 8 ) 2 5 1 –2 5 6
8. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of
cancer cachexia. Curr Opin Clin Nutr Metab Care 2003;6:401–6.
9. Lee.S, Choe J, Kim H, Sung J, high sensitivity c-reactive protein and cancer, J
epidemiol 2011, 21(3), 161-168
10. S. Lee, S. Y. Oh, S. H. Kim et al., “Prognostic significance of neutrophil
lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer
patients treated with FOLFOX chemotherapy,” BMC Cancer, vol. 13, article
350, 2013.
11. H.-Y. Hung, J.-S. Chen, C. Y. Yeh et al., “Effect of preoperative neutrophillymphocyte ratio on the surgical outcomes of stage II colon cancer patients
who do not receive adjuvant chemotherapy,” International Journal of
Colorectal Disease, vol. 26, no. 8, pp. 1059–1065, 2011.
12. Y.Kishi, S.Kopetz, Y. S. Chun,M.Palavecino, E. K. Abdalla, and J.-N. Vauthey,
“Blood neutrophil-to-lymphocyte ratio predicts survival in patients with
colorectal livermetastases treated with systemic chemotherapy,” Annals of
Surgical Oncology, vol. 16, no. 3, pp. 614–622, 2009.
13. A. M. di Giacomo, L. Calabr`o, R. Danielli et al., “Longterm survival and
immunological parameters in metastatic melanoma patients who responded to
ipilimumab 10 mg/kg within an expanded access programme,” Cancer
Immunology, Immunotherapy, vol. 62, no. 6, pp. 1021–1028, 2013.
14. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A,
and Cramer DW, Prognostic Significance and Predictors of the Neutrophil-toLymphocyte Ratio in Ovarian Cancer Gynecol Oncol. 2014 March ; 132(3):
542–550.
15. W.He, C. Yin, G.Guo et al., “Initial neutrophil lymphocyte ratio is superior to
platelet lymphocyte ratio as an adverse prognostic and predictive factor in
metastatic colorectal cancer,” Medical Oncology, vol. 30, no. 1, article 439,
2013.
16. J. F. Feng, Y. Huang, Q. Zhao, and Q. X. Chen, “Clinical significance of
preoperative neutrophil lymphocyte ratio versus platelet lymphocyte ratio in
patients with small cell carcinoma of the esophagus,” The ScientificWorld
Journal, vol. 2013,Article ID 504365, 7 pages, 2013.
17. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S,
Thavaramara T, Platelet to lymphocyte ratio as a prognostic factor for
epithelial ovarian cancer, in J Gynecol Oncol Vol. 23, No. 4:265-273
18. N. MacDonald, “Terminology in cancer cachexia: importance and status,”
Current Opinion in Clinical Nutrition andMetabolic Care, vol. 15, no. 3, pp.
220–225, 2012.
19. M. J. Proctor,D. S.Morrison,D. Talwar et al., “An inflammationbased
prognostic score (mGPS) predicts cancer survival independent of tumour site:
a Glasgow Inflammation Outcome Study,” British Journal of Cancer, vol. 104,
no. 4, pp. 726–734, 2011.
20. Berek JS. Natarajan Sathima. Ovarian and Fallopian Tube Cancer. Berek &
Novak‟s Gynecology. Lippincott William and Wilkins. 14th edition.2007; 1457
– 1503
21. Berek JS, Friedlander M, Hacker NF, Epithelial Ovarian, Fallopian Tube, and
Peritoneal Cancer, in berek and Hacker's Gynecologic Oncology, 5th Edition.
Lippincott Williams & Wilkins 2010 p.444-509
22. Tone AA, Salvador S, Finlayson SJ et al, The Role of the Fallopian Tube in
Ovarian Cancer, Clinical Advances in Hematology & Oncology Volume 10,
Issue 5 May 2012, pp 296-306
23. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma
that originates in the distal fallopian tube. J Pathol. 2007;211:26-35.
24. Jordan SJ, Green AC, Whiteman DC, et al. Serous ovarian, fallopian tube and
primary peritoneal cancers: a comparative epidemiological analysis. Int J
Cancer. 2008;122:1598-1603.
25. Macciò A and Madeddu C, Inflammation and Ovarian Cancer, Ovarian Cancer
– Basic Science Perspective. 2012 Report No: ISBN: 978-953-307-812-0
26. Wang C, Sun C, C-Reactive Protein and Malignancy: Clinico-Pathological
Association and Therapeutic Implication. Reveiw Article, Chang Gung Med J
2009;32:471-82
27. A. T. Toriola, K. Grankvist, C. B. Agborsangaya, A. Lukanova, M. Lehtinen &
H.-M. Surcel, Changes In Pre-Diagnostic Serum C-Reactive Protein
Concentrations And Ovarian Cancer Risk: A Longitudinal Study, in Annals of
Oncology 22: 1916–1921, 2011.
28. Shan W, Liu J. Inflammation; a hidden path to breaking the spell of ovarian
cancer. Cell Cycle 2009; 8(19): 3107–3111.
29. Partheen K, New Prognostic Markers In Stage III Serous Ovarian
Adenocarcinomas, in thesis, Department of Oncology Institute of Clinical
Sciences The Sahlgrenska Academy at University of Gothenburg, 2008.
30. Elshabrani S, Farid A et.al, Evaluation of C-Reactive Protein as a Probable
Factor for Cancer Diagnosis, life sience journal, 2012, 9 (4)
31. Hefler L A, Concin N et al, Serum C-Reactive Protein as Independent
Prognostic Variable in Patiens With Ovarian Cancer, Clin Cancer Res
2008;14(3)
32. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor
proliferative
activity
in
patients
with
colorectal
carcinoma.
Cancer
1999;85:2526–31.
33. Mc Keown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship
between circulating concentrations of Creactive protein, inflammatory
cytokines and cytokine receptors in patients with non-small-cell lung cancer.
Br J Cancer 2004;91:1993–5.
34. Peralta R, Rubery BA, Langenfeld SC. Hypoalbuminemia : treatment and
medication. eMedicine Critical Care.2010.1-6.
35. Gupta D, Lis CG, Pretreatment serum albumin as a predictor of cancer
survival: A systematic review of the epidemiological literature, in Gupta and
Lis Nutrition Journal 2010.
36. Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotte P,
Lerebours E, Michel P: Baseline nutritional status is predictive of response to
treatment and survival in patients treated by definitive chemoradiotherapy for
a locally advanced esophageal cancer. Am J Gastroenterol 2007, 102:25572563.
37. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K: Inflammation-based
prognostic score is a novel predictor of postoperative outcome in patients with
colorectal cancer. Ann Surg 2007, 246:1047-1051.
38. Gupta D, Lammersfeld CA, Vashi PG, Lis CG. A longitudinal analysis
investigating the impact of improvement in serum albumin scores on survival
in ovarian cancer. Clinical Ovarian cancer. 2009;2(2):106-111.
39. Donohoe CL, Ryan AM, , cancer cachexia : mechanisms and clinical
implications, review article, hindawi publishing corp. Vol 2011.
40. Lu H, Ouyang W et al. Inflammation, a key event in cancer development
,Subject Review, mol.cancer res 2006 4(6), april 2006
41. Drenberg DC. Saunders OB. Wilbanks DG et al. Urinary Angiostatin levels are
elevated in patients with Epithelial ovarian Cancer. Gynecologic Oncology.
USA. 117:2010.117-124
42. M. J. Proctor, P. G. Horgan, D. Talwar, C. D. Fletcher, D. S. Morrison, and D.
C. McMillan, “Optimization of the systemic inflammation-based Glasgow
prognostic score: a Glasgow InflammationOutcome Study,” Cancer, vol. 119,
no. 12, pp. 2325– 2332, 2013.
43. D. C. McMillan, “The systemic inflammation-based Glasgow prognostic score:
a decade of experience in patients with cancer,” Cancer Treatment Reviews,
vol. 39, no. 5, pp. 534–540,2013.
44. Suh KS, Sang WP, Angelica C1, et al.
Ovarian cancer biomarkers for
molecular biosensors and translational medicine Expert Rev. Mol. Diagn.
10(8), 1069–1083. 2010.
45. Former Anglia Cancer Network. Cancer Research UK. Http://ecric.org.uk/
46. Rauh-Hain AJ, Del Carmen MG, Recurrent Epithelial Ovarian Cancer: An
Update on Treatment. cancer network home of the journal oncology. Reveiw
article 2013. Published on Cancer Network http://www.cancer net work.com
47. FIGO 1988 VS FIGO 2013 Ovarian Cancer Staging Guide.
48. Madiyono B, Mz Sm, Sastoasmoro S, Budiman I, Purwanto S H. Perkiraan
Besar Sampel. Dalam Sastroasmoro S, Ismael S. Dasar Dasar Metodologi
Penelitian Klinis. Jakarta: Sagung Seto; 2010. p. 323.
49. Hs-CRP Kit, Pramita Laboratorium Leaflet. 2012
50. Pemeriksaan CRP, Prosedur Tetap Pelayanan Laboratorium, RSUP H.Adam
Malik, Medan, Juli 2012
51. Bmi asia WHO expert consultation in Appropriate body-mass index for Asian
populations and its implications for policy and intervention Strategies. Public
Health. The Lancet • Vol 363 • January 10, 2004